Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.70 |
| ▸ | SMYD3 | Q9H7B4 | 7/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15426758 | 0.87 | ADORA1 (0.77) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL15425807 | 0.81 | ADORA1 (0.81) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL15425800 | 0.80 | ADORA1 (0.74) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL15426757 | 0.80 | ADORA1 (0.74) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL8355377 | 0.80 | ADORA1 (0.62) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL4251032 | 0.79 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL4251031 | 0.79 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL4251034 | 0.79 | ADORA1 (0.87) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL4496406 | 0.78 | ADORA1 (0.78) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL8353560 | 0.75 | ADORA1 (0.66) | ADORA1ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018361-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140018361-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018361-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK4, IRAK1 | ADORA1 2639/4885ADORA2A 2278/4885SMYD3 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.